PA8766901A1 - Nuevo derivado de heterocicliden acetamida - Google Patents

Nuevo derivado de heterocicliden acetamida

Info

Publication number
PA8766901A1
PA8766901A1 PA20088766901A PA8766901A PA8766901A1 PA 8766901 A1 PA8766901 A1 PA 8766901A1 PA 20088766901 A PA20088766901 A PA 20088766901A PA 8766901 A PA8766901 A PA 8766901A PA 8766901 A1 PA8766901 A1 PA 8766901A1
Authority
PA
Panama
Prior art keywords
group
salt
compound
receiver
composite
Prior art date
Application number
PA20088766901A
Other languages
English (en)
Inventor
Uchida Hideharu
Ogawa Shinichi
Makabe Muneyoshi
Maeda Yoshitaka
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8766901(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of PA8766901A1 publication Critical patent/PA8766901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA PRESENTE INVENCION SE REFIERE A UN COMPUESTO, REPRESENTADO POR LA FORMULA (I' ): (EN DONDE M, N, Y P CADA UNO REPRESENTA 0 HASTA 2; Q REPRESENTA 0 Ó 1; R1 REPRESENTA HALOGENO, UN GRUPO HIDROCARBURO, UN GRUPO HETERICICLICO, UN GRUPO ALCOXI, UN GRUPO ALCOXICARBONILO, UN GRUPO SULFAMOILO, UN GRUPO CN, O UN GRUPO NO2 O SIMILARES; R2 REPRESENTA HALOGENO, AMINO, UN GRUPO HIDROCARBURO, UN GRUPO HETEROCICLICO AROMATICO, O UN GRUPO OXO; X1 REPRESENTA O, -NR3- O -S(O)R-; Q' REPRESENTA UN GRUPO HETEROARILALQUILO, UN GRUPO ARILO SUSTITUIDO, O UN GRUPO ARALQUILO; LA PORCIÓN CICLO REPRESENTA UN ANILLO HETEROARILO O UN ANILLO ARILO; Y LA LINEA PUNTEADA REPRESENTA UN ISOMERO-E O UN ISOMERO-Z), UNA SAL COMPUESTO, O UN SOLVATO DEL COMPUESTO O LA SAL. UNA COMPOSICION FARMACEUTICA Y UN ANTAGONISTA DEL RECEPTOR DEL TIPO I POTENCIAL DEL RECEPTOR TEMPORAL (TRPVI) CADA UNO. UNA COMPOSICION FARMACEUTICA, CARACTERIZADA PORQUE COMPRENDE COMO UN INGREDIENTE ACTIVO, AL MENOS UN COMPUESTO REPRESENTADO POR LA FORMULA (I) DE CONFORMIDAD CON LA REIVINDICACION 1, UNA SAL DEL COMPUESTO FARMACEUTICAMENTE ACEPTABLE, Y UN SOLVATO DEL COMPUESTO O LA SAL. UN ANTAGONISTA DEL RECEPTOR DE TIPO I POTENCIAL DEL RECEPTOR TEMPORAL (TRPV1) CARACTERIZADO PORQUE COMPRENDE, COMO UN INGREDIENTE ACTIVO, AL MENOS UNO DE LOS COMPUESTOS REPRESENTADOS (I) DE CONFORMIDAD CON LA REIVINDICACION 1, UNA SAL DEL COMPUESTO FARMACEUTICAMENTE ACEPTABLE, Y UN SOLVATO DEL COMPUESTO O LA SAL.
PA20088766901A 2007-01-24 2008-01-24 Nuevo derivado de heterocicliden acetamida PA8766901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007014372 2007-01-24

Publications (1)

Publication Number Publication Date
PA8766901A1 true PA8766901A1 (es) 2009-06-23

Family

ID=39644589

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088766901A PA8766901A1 (es) 2007-01-24 2008-01-24 Nuevo derivado de heterocicliden acetamida

Country Status (14)

Country Link
EP (1) EP2128157A4 (es)
JP (1) JPWO2008091021A1 (es)
KR (1) KR20090107068A (es)
CN (1) CN101589038A (es)
AR (1) AR065014A1 (es)
AU (1) AU2008208224A1 (es)
CA (1) CA2676020A1 (es)
CL (1) CL2008000202A1 (es)
CO (1) CO6210825A2 (es)
MX (1) MX2009007954A (es)
PA (1) PA8766901A1 (es)
PE (1) PE20081692A1 (es)
TW (1) TW200902002A (es)
WO (1) WO2008091021A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4754566B2 (ja) 2005-07-22 2011-08-24 持田製薬株式会社 新規なヘテロシクリデンアセトアミド誘導体
NZ571706A (en) * 2006-04-18 2012-06-29 Abbott Lab Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
JP2011201776A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体
CA2728405A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Chromane derivatives as trpv3 modulators
JP2011201778A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ｐ−置換アリールアセトアミドを有するヘテロシクリデン誘導体
JP2011201777A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
CN103635458B (zh) 2011-03-25 2016-10-19 艾伯维公司 Trpv1拮抗剂
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CA3150748A1 (en) * 2019-08-23 2021-03-04 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivative
KR102334947B1 (ko) * 2020-04-22 2021-12-06 주식회사 제이맥켐 Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309621D0 (en) 1993-05-11 1993-06-23 Wellcome Found Amide derivatives and their therapeutic use
NZ271454A (en) 1993-08-26 1997-07-27 Yamanouchi Pharma Co Ltd Difluoro substituted benzazepine derivatives and pharmaceutical compositions
DE19620170A1 (de) 1996-05-20 1997-11-27 Wolfgang Prof Dr Dr Pfleiderer Nucleosid-Derivate mit photolabilen Schutzgruppen
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
AU1309701A (en) 1999-11-15 2001-05-30 Nissan Chemical Industries Ltd. Hydrazone compounds and pesticides
US6120964A (en) 1999-12-15 2000-09-19 Eastman Kodak Company 2-(1,2-benzisothiazol-3(2H)-ylidene 1,1-dioxide)acetamides negative charge control agents for electrostatographic toners and developers
EP1445253B1 (en) 2001-11-16 2009-08-05 Astellas Pharma Inc. 4,4-difluoro-1, 2, 3, 4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
US7582657B2 (en) * 2001-12-10 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
ATE416168T1 (de) * 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
CA2486530A1 (en) * 2002-05-29 2003-12-11 Amgen Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders
CA2510471A1 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
WO2004069792A2 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid vr1 receptor
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
US7585878B2 (en) 2003-06-12 2009-09-08 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
ATE399782T1 (de) 2003-09-22 2008-07-15 Euro Celtique Sa Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
JP4667384B2 (ja) 2003-10-07 2011-04-13 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005044802A2 (en) 2003-11-08 2005-05-19 Bayer Healthcare Ag Tetrahydro-quinolinylurea derivatives as vrl antagonists
US7553848B2 (en) 2004-01-23 2009-06-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005095329A1 (en) 2004-03-31 2005-10-13 Pfizer Japan Inc. Substituted benzamide compounds as vr1 receptor antagonists
JP4018739B2 (ja) 2004-07-15 2007-12-05 日本たばこ産業株式会社 縮合ベンズアミド化合物及びバニロイド受容体１型（ｖｒ１）活性阻害剤
EP1799661A1 (en) 2004-10-08 2007-06-27 AstraZeneca AB New hydroxymethylbenzothiazoles amides
WO2006058338A2 (en) 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
ES2255848B1 (es) 2004-12-16 2007-07-01 Consejo Superior Investig. Cientificas Derivados de isoquinolina como inhibidores de calpaina.
JP2007014372A (ja) 2005-07-05 2007-01-25 Kariya Mokuzai Kogyo Kk 椅子
JP4754566B2 (ja) * 2005-07-22 2011-08-24 持田製薬株式会社 新規なヘテロシクリデンアセトアミド誘導体

Also Published As

Publication number Publication date
JPWO2008091021A1 (ja) 2010-05-20
MX2009007954A (es) 2009-08-07
CN101589038A (zh) 2009-11-25
CL2008000202A1 (es) 2009-10-02
TW200902002A (en) 2009-01-16
PE20081692A1 (es) 2008-12-18
EP2128157A1 (en) 2009-12-02
AU2008208224A1 (en) 2008-07-31
KR20090107068A (ko) 2009-10-12
CO6210825A2 (es) 2010-10-20
WO2008091021A1 (ja) 2008-07-31
AR065014A1 (es) 2009-05-13
CA2676020A1 (en) 2008-07-31
EP2128157A4 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
PA8766901A1 (es) Nuevo derivado de heterocicliden acetamida
CY1124284T1 (el) Ενωσεις σπειρο[3η-ινδολο-3,2'-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53
ECSP088129A (es) Derivado novedoso de heterocicliden acetamida
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
AR065280A1 (es) Agentes antiparasitarios
UY30349A1 (es) Ligandos del receptor de acetilcolina de tipo nicotinico
TR201903556T4 (tr) Muskarinik reseptör antagonisti ve beta 2 adrenerjik reseptör agonisti aktivitesine sahip diamid bileşikleri.
CY1115175T1 (el) Ενωσεις 9-υποκατεστημενης-8-οξο-αδενινης ως ρυθμιστες υποδοχεων τυπου toll (tlr7)
PH12016500806A1 (en) Urea derivative or pharmacologically acceptable salt thereof
ECSP10010585A (es) Compuestos de 2- imido- 3- metil pirrolo pirimidinona fenilo- sustituidos como inhibidores bace- 1, composiciones, y su uso
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
ECSP10010601A (es) Ligandos de receptor de estrogeno novedosos
RS20090208A (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
MA29136B1 (fr) Agents de potentialisation de recepteurs du glutamate
CO6491083A2 (es) Profarmacos que comprenden un conugado de insulina-conector
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
DOP2010000226A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
ATE534625T1 (de) Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung
AR063119A1 (es) Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1)